Your browser doesn't support javascript.
loading
Clinical Impact of C-myc Oncogenic Diversity on Solid and Lymphoid Malignancies.
Papouliakos, Sotirios; Chrysovergis, Aristeidis; Papanikolaou, Vasileios; Spyropoulou, Despoina; Papanastasiou, Georgios; Asimakopoulos, Asimakis D; Mastronikoli, Sofianiki; Stathopoulos, Panagiotis; Roukas, Dimitrios; Adamopoulou, Maria; Tsiambas, Evangelos; Peschos, Dimitrios; Pantos, Pavlos; Ragos, Vasileios; Mastronikolis, Nicholas; Kyrodimos, Efthymios.
Afiliación
  • Papouliakos S; Department of Otolaryngology,''Gennimatas'' GNA Hospital, Athens, Greece.
  • Chrysovergis A; Department of Otolaryngology, ''ELPIS'' GNA Hospital, Athens, Greece.
  • Papanikolaou V; Department of Otolaryngology, ''Sotiria'' GNA Hospital, Athens, Greece.
  • Spyropoulou D; Department of Radiation Oncology, Medical School, University of Patras, Patras, Greece.
  • Papanastasiou G; Department of Otorhinolaryngology, Head and Neck Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece.
  • Asimakopoulos AD; Department of Otorhinolaryngology, Head and Neck Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece.
  • Mastronikoli S; Brighton and Sussex Medical School, Brighton, UK.
  • Stathopoulos P; Department of Maxillofacial Surgery, "KAT", GNA Hospital, Athens, Greece.
  • Roukas D; Department of Psychiatry, 417 Veterans Army Hospital, Athens, Greece.
  • Adamopoulou M; Biomedical Sciences Program, Department of Science and Mathematics, Deree American College, Athens, Greece.
  • Tsiambas E; Department of Cytology, 417 Veterans Army Hospital, Athens, Greece.
  • Peschos D; Department of Physiology, Medical School, University of Ioannina, Greece.
  • Pantos P; First Department of Otolaryngology, "Hippocration" Hospital, Medical school, National and Kapodistrian University of Athens, Athens, Greece.
  • Ragos V; Department of Otorhinolaryngology, Head and Neck Surgery, Lausanne University Hospital, Lausanne, Switzerland; Department of Maxillofacial Surgery, Medical School, University of Ioannina, Ioannina, Greece.
  • Mastronikolis N; Department of Otolaryngology, Medical School, University of Patras, Greece.
  • Kyrodimos E; First Department of Otolaryngology, "Hippocration" Hospital, Medical school, National and Kapodistrian University of Athens, Athens, Greece.
Maedica (Bucur) ; 19(2): 355-359, 2024 Jun.
Article en En | MEDLINE | ID: mdl-39188831
ABSTRACT

INTRODUCTION:

Onset and progression of malignant tumors is a multistep process including a variety of gross chromosomal and specific genes' deregulation. Among oncogenes that are frequently altered in solid and also in hematological malignancies, the C-myc (gene locus 8q24.21) plays a pivotal role. C-myc is a proto-oncogene encoding for a nuclear phosphoprotein implicated in cell cycle progression, apoptosis and cellular differentiation and transformation.

OBJECTIVE:

The purpose of the current molecular review was to explore the differences of C-myc oncogenic activity in solid and lymphoid malignancies that modify its clinical impact on them. MATERIAL AND

METHOD:

A systematic review of the literature in the international database PubMed was carried out. The year 2010 was set as a prominent time limit for the publication date of articles in the majority of them, whereas specific references of great importance and historical value in the field of C-myc gene discovery and analysis were also included. The following keywords were used C-myc, oncogene, signaling pathway, malignancies, carcinoma, lymphoma. A pool of 43 important articles were selected for the present study at the basis of combining molecular knowledge with new targeted therapeutic strategies.

RESULTS:

C-myc oncogene demonstrates two different mechanisms of deregulation amplification, mutation and translocation patterns. These particular aspects of gene alteration are unique for solid and non-solid (hematological) malignancies, respectively.

CONCLUSIONS:

C-myc is characterized by diversity regarding its deregulation mechanisms in malignancies derived from different tissues. C-myc translocation is sporadically combined with amplification ("complicon" formation) or mutations creating exotic genetic signatures. This "bi-phasic" C-myc deregulation model in the corresponding malignant tumor categories clinically affects the corresponding patients, also modifying the targeted therapeutic strategies on them.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Maedica (Bucur) Año: 2024 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Rumanía
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Maedica (Bucur) Año: 2024 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Rumanía